- Home
- WRAP vs TLSA Comparison
WRAP vs TLSA Comparison
Compare WRAP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRAP | TLSA |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 155.2M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WRAP | TLSA |
|---|---|---|
| Price | $1.47 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 228.0K | 108.5K |
| Earning Date | 04-06-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,507,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.20 | $0.73 |
| 52 Week High | $3.23 | $2.60 |
Technical Indicators
Market Signals| Indicator | WRAP | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 39.47 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.52 | $1.56 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 1.72 | 13.79 |
Price Performance
Historical ComparisonAbout WRAP Wrap Technologies Inc.
Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel worldwide. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.